The use of radiolabelled monoclonal antibodies in the diagnosis of colorectal carcinomas

Clinical Immunotherapeutics

Volumn 6, Issue 3, 1996, Pages 200-210

  Nabi, Hani A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; SATUMOBAB PENDETIDE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; ISOTOPE LABELING; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0029758414     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259519     Document Type: Review

References (56)

1. Gelfand DW, Oil DJ. Colon cancer screening: where radiology fits in. Diagn Imag 1993 July; 75-7
2. Blot WJ. The epidemiology of cancer. In: Cecil texthook of medicine. Philadelphia: WB Saunders. 1992: 1027-32
3. Levin B. Neoplasms of the large and small intestine. In: Cecil textbook of medicine. Philadelphia: WB Saunders, 1992: 713-20
4. Collier BD, Abdel-Nabi H. Doerr RJ. et al. Immunoscintigraphy performed with In-111 -labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992; 185: 179-86
5. Doerr RJ. Abdel-Nabi H. Baker JM. et al. Detection of primary colorectal cancer with indium 111 monoclonal antibody B72.3. Arch Surg 1990: 125: 1601-5
6. Galandiuk S. Immunoscintigraphy in the surgical manageinent of colorectal cancer. J Nucl Med 1993; 34: 541-44
7. Galandiuk S, Wieand HS. Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma ol the colon and rectum. Surg Gynecol Obstet 1992; 174: 27-32
8. Collier BD. Foley WD, Current imaging strategies for colorectal cancer. J Nucl Med 1993; 34: 537-40
9. Nabi HA, Doerr RJ. Radiolabeled monoclonal antibody imaging (immunoscintigraphy) of colorectal cancers: current status and future perspectives. Am J Surg 1992; 163: 448-56
10. Moertel CG. Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270: 943 7
11. Northover JMA. Carcinoembryonic antigen and recurrent coloreclal cancer. Gut 1986; 27: 1 17-22
12. Sandier RS, Freund DA, Herbst ÇA, et al. Cost-effectiveness of post-operative carcinoembryonic antigen monitoring in colorectal cancer. Cancer 1984; 53: 193-8
13. Huband JE. Hudson NJ, Parsons CA. The use of computed tomography in recurrent rectal tumors. Radiology 1980: 134: 677-82
14. Thompson WM. Halvorsen RA. Computed tomographic staging of gastrointestinal malignancies. Part II. The small bowel, colon and rectum. Invest Radiol 1987; 22: 96-105
15. Thompson WM, Halvorsen RA, Foster Jr WL, et al. Preoperalive and postoperative CT staging of rectosigmoid carcinoma. AJR Am J Roent 1986: 146: 703-10
16. Frecny PC, Marks WM. Ryan JA. et al. Colorectal carcinoma evaluation with CT: preoperative staging and detection of postoperative recurrence. Radiology 1986; 158: 347-53
17. Kelvin FM. Korobkin M. Heaston DK. et al. The pelvis after surgery for rectal carcinoma: serial CT observations with emphasis on nonneoplastic features. AJR Am J Roent 1983; 141: 959-64
18. Lee JKT. Santley RJ. Sagel SS, et al. CT appearance of the pelvis alter abdomino-perineal resection for rectal carcinoma. Radiology 1981: 141: 737-41
19. Kohler G. Milstein C Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975: 256: 495-7
20. Goldenberg DM. Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992: 33: 803-14
21. Doerr RJ, Abdel-Nabi H. Merchant B. Indium-Ill ZCE 025 immunoscintigraphy in occult recurrent colorectal cancer with elevated carcinoembryonic antigen le\el. Arch Surg 1990: 125:226-9
22. Haseman MK, Brown DW. Keeling ÇA. et al. Radioimmunodetection of occult carcinoembryonic antigen-producing can cer.J Nucl Med 1992:33: 1750-7
23. Doerr RJ. Herrera L. Abdel-Nabi HA. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer. Cancer 1993; 71: 4241-7
24. Colther D. Horan Hand P. Nuti M. et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sei USA 1981; 78: 3199-203
25. Carrasquillo JA. Sugarbaker P, Colcher D. et al. Radioimmunoscintigraphy of colon cancer with iodine-131 labeled B72.3 monoclonal antibody. J Nucl Med 1988; 29: 1022-30
26. Maguire RT, Schmelter RJ. Pascucci VL. et al. Immunoscintigraphy of colorectal adenocarcinoma: results with site-specific radiolabeled B72.3 (inln-CYT-l()3). Antibody Immunoconj Radiopharm 1989: 2: 257-69
27. Doerr RJ. Abdel-Nabi H. Krag D. et al. Radiolabeled antibody imaging in the management of colorectal cancer: results of a multicenter clinical study. Ann Surg 1991; 214: 118-24
28. Carrasquillo JA. Sugarbaker R Colcher D. et al. Peritoneal carcinomatosis: imaging with intraperitoneal injection of 1-131 labeled B72.3 monoclonal antibody. Radiology 1988; 167: 35-40
29. Rodwell JD. Alvares VL. Lee C. et al. Site specific covalent modification of monoclonal antibodies: in vivo and in vitro evaluations. Proc Natl Acad Sei USA 1986; 83; 2632-6
30. Nabi HA. Radiolabeled antibodies in clinical nuclear medicine: a technology coming of age. In: Freeman LM, editor. Nuclear Medicine Annual 1993. New York: Raven Press. 1993: 1-27
31. Nabi HA. Enhanced tumor detection w ith SPECT. and its contribution in the evaluation of patients with colorectal carcinoma by use of In-111 monoclonal antibody scintigraphy. Radiology 1993: 189: 334
32. Neal CE. Abdel-Nabi H. Clinical immunoscintigraphy ot recurrent colorectal carcinoma. Appl Radiol 1994: 32-9
33. Corman ML. Galandiuk S. Block GE. et al. Immunoscintigraphy w ith ' ' 'In-satumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management. Dis Colon Rectum 1994; 37: 129-37
34. Abdel-Nabi H. Doerr RJ. Chan HW. el al. In-111 labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma patients: safety, sensitivity, and preliminary clinical applications. Radiology 1990: 175: 163-71
35. Abdel-Nabi H. Doerr RJ. Detection of recurrent colorectal can cer: an algorithm for immunoscintigraphy. Appl Radiol 1994 Dec; 11-16
36. Smith LM. Unger M. Bartholomew R. Antimouse responses to monoclonal antibody (MoAb) therapy in human patients. J Nucl Med 1986:27:'942
37. Shaw 1er DL. Bartholomew RM, Smith LM. et al. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530-5
38. Schroff RW. Foon KA. Beatty SM. et al. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985: 45: 879-85
39. Cytogen Corporation/Knoll Pharmaceutical Company. OncoScint CR/ÜV kit (satumomab pendetide). Prescribing information 1992
40. Perkins AC. Pimm MV. Powell MC. The implications of patients antibody response for the clinical usefulness of immunoscintigraphy. Nucl Med Commun 1988: 9: 273-82
41. Abdel-Nabi H. Harwood SJ. Collier BD. et al. Repeated administration of OneoScint'1 (In-111-CYT-103) in coloreclal carcinoma patients: interim report of safety, efficacy and HAMA development. J Nucl Med 1993: 34: 213P
42. Abdel-Nabi H. Maroli A. HAMA response to repeated administration of In-111 satumomab pendetide (OncoScint): frequency and patterns of development [abstract]. Proc Am Assoc Cancer Res 1994: 35: 218
43. Hansen HJ, LaFontaine G, Newman ES, et al. Solving the problem of antibody interference in commercial 'sandwich' type immunoassay of carcinoembryonic antigen. Clin Chem 1989; 35: 146-51
44. Khazaeli MB, Saleh MN, Liu TP, et al. Pharmacokinetics and immune response of nll-chimeric mouse/human B72.3 (human gamma4) monoclonal antibody in humans. Cancer Res 1991; 51: 5461-6
45. Buchegger F, Mach JP, Pèlegrin A, et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med 1995; 36: 420-9
46. Bosslet K, Lüben G, Schwarz A, et al. Immunohistochemical localization and molecular characteristics of three monoclonal antibody defined epitopes on carcinoembryonic antigen (CEA). Int J Cancer 1985; 36: 75-84
47. Schwarz A, Steinsträsser A. A novel approach toTc-99m labeled monoclonal antibodies. J Nucl Med 1987; 38: 721
48. Lind P, Lechner P. Arian-Schad K, et al. Anti-carcinoembryonic antigen immunoscintigraphy (technetium-99m monoclonal antibody BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma. J Nucl Med 1991; 32: 1319-25
49. 2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res 1989; 49: 3095-4103
50. Moffat FL, Pinsky CM, Petrelli N, et al. Clinical utility of imaging with the IMMU-4 Tc-Fab' fragment in patients undergoing surgery for carcinoma of the colon or rectum (abstract]. Proceedings of the Society of Surgical Oncology Meeting: 1995 Mar 23-26; Boston
51. Lechner P, Lind P, Binter G, étal. Anti-carcinoembryonic antigen immunoscintigraphy withaCWnTcFab'fragment(lmmu4) in primary and recurrent colorectal cancer: a prospective study. Dis Colon Rectum 1993; 36: 930-5
52. Podoloff DA, Patt YZ, Curley SA, et al. Imaging of colorectal carcinoma with technetium 99m radiolabeled Fab' fragments. Semin Nucl Med 1993; 2: 89-98
53. Patt YZ. Podoloff DA, Curley S, et al. Technetium-99m labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J ClinOncol 1994; 12:489-95
54. Moffat Jr FL, Vargas-Cuba RD, Serafini AN, et al. Radioimmunodetection of colorectal carcinoma using technetium-99m labeled Fab' fragments of the IMMU-4 anti-carcinoembryonic antigen monoclonal antibody. Cancer 1994; 73: 836-45
55. Behr T, Becker W, Hannappel E, et al. Targeting of liver métastases of colorectal cancer with IgG F(ab'h, and Fab anti-carcinoembryonic antigen antibodies labeled with 99ltTTc: the role of metabolism and kinetics. Cancer Res 1995; 55 Suppl.: 5777-85
56. Abdel-Nabi H, Doerr RJ. Indium-111 labeled MoAb detection of liver metastasis from colorectal cancer: histopathological and immunoscintigraphic correlates. Eur J Nucl Med 1990; 16 Suppl.: 101